Evidence map›Paper›PMID 32974644›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

Incorporating Real-time Influenza Detection Into the Test-negative Design for Estimating Influenza Vaccine Effectiveness: The Real-time Test-negative Design (rtTND).

Leora R Feldstein, Wesley H Self, Jill M Ferdinands, Adrienne G Randolph, Michael Aboodi, Adrienne H Baughman, Samuel M Brown, Matthew C Exline, D Clark Files, Kevin Gibbs and 16 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Designs for Vaccine Studies.Annual review of statistics and its application · 2025
    Article
  2. Vaccine Effectiveness Against Influenza A-Associated Hospitalization, Organ Failure, and Death: United States, 2022-2023.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  3. Article
  4. Article
  5. Influenza Vaccine Effectiveness for Prevention of Severe Influenza-Associated Illness Among Adults in the United States, 2019-2020: A Test-Negative Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Leora R FeldsteinInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-4430-6760
Wesley H SelfVanderbilt University Medical Center, Nashville, Tennessee, USA.
Jill M FerdinandsInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Adrienne G RandolphDepartment of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts, USA.
Michael AboodiDivision of Critical Care Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.
Adrienne H BaughmanVanderbilt University Medical Center, Nashville, Tennessee, USA.
Samuel M BrownDivision of Pulmonary/Critical Care, Department of Medicine, Intermountain Medical Center and University of Utah, Murray, Utah, USA.
Matthew C ExlineThe Ohio State University, College of Nursing, Columbus, Ohio, USA.
D Clark FilesPulmonary Critical Care Allergy and Immunological Diseases, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Kevin GibbsPulmonary Critical Care Allergy and Immunological Diseases, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Adit A GindeDepartment of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
Michelle N GongDivision of Critical Care Medicine, Division of Pulmonary Medicine, Department of Medicine, Department of Epidemiology and Population Health, Montefiore Healthcare System, Albert Einstein College of Medicine, Bronx, New York, USA.
Carlos G GrijalvaVanderbilt University Medical Center, Nashville, Tennessee, USA.
Natasha HalasaDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Akram KhanDepartment of Pulmonary and Critical Care, Oregon Health and Science University, Portland, Oregon, USA.
Christopher J LindsellVanderbilt University Medical Center, Nashville, Tennessee, USA.
Margaret NewhamsDepartment of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts, USA.
Ithan D PeltanDivision of Pulmonary/Critical Care, Department of Medicine, Intermountain Medical Center and University of Utah, Murray, Utah, USA.
Matthew E PrekkerDepartment of Medicine, Division of Pulmonary and Critical Care and Department of Emergency Medicine, Hennepin County Medical Center and the University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Todd W RiceVanderbilt University Medical Center, Nashville, Tennessee, USA.
Nathan I ShapiroDepartment of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Jay SteingrubDivision of Critical Care Pulmonary Medicine, Baystate Medical Center, Springfield, Massachusetts, USA.
H Keipp TalbotVanderbilt University Medical Center, Nashville, Tennessee, USA.
M Elizabeth HalloranDepartment of Biostatistics, University of Washington, Seattle, Washington, USA.
Manish PatelInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Influenza Vaccine Effectiveness in the Critically Ill (IVY) Investigators and the Pediatric Intensive Care Influenza Vaccine Effectiveness (PICFLU-VE) Investigators

Funding

Methods for Evaluating Vaccine EfficacyR37AI032042 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HALLORAN, M ELIZABETH · 2010 to 2019
$5.1M
Mentoring in transmission of influenza and strategies for preventionK24AI148459 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GRIJALVA, CARLOS G · 2020 to 2024
$893k
Prehospital Activation of ED Teams to Improve Sepsis CareK23GM129661 · NIGMS · IHC HEALTH SERVICES, INC. · PI PELTAN, ITHAN DANIEL · 2019 to 2023
$786k
CDC HHSNIAID NIH HHS K24 AI148459NIAID NIH HHS R37 AI032042NIGMS NIH HHS K23 GM129661
6 · The paper itself

Abstract

With rapid and accurate molecular influenza testing now widely available in clinical settings, influenza vaccine effectiveness (VE) studies can prospectively select participants for enrollment based on real-time results rather than enrolling all eligible patients regardless of influenza status, as in the traditional test-negative design (TND). Thus, we explore advantages and disadvantages of modifying the TND for estimating VE by using real-time, clinically available viral testing results paired with acute respiratory infection eligibility criteria for identifying influenza cases and test-negative controls prior to enrollment. This modification, which we have called the real-time test-negative design (rtTND), has the potential to improve influenza VE studies by optimizing the case-to-test-negative control ratio, more accurately classifying influenza status, improving study efficiency, reducing study cost, and increasing study power to adequately estimate VE. Important considerations for limiting biases in the rtTND include the need for comprehensive clinical influenza testing at study sites and accurate influenza tests.

Indexed as

Influenza, HumanInfluenza VaccinesBiasCase-Control StudiesHumansTreatment OutcomeVaccinationInfluenza Vaccinesclinical testinginfluenzareal-time test-negative designtest-negative designvaccine effectiveness

Identifiers

PMID32974644
PMCPMC8096266

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.